endo-avoid-preop-medical-therapy

name	endo-avoid-preop-medical-therapy
description	The guideline recommends against routine preoperative medical therapy (e.g., somatostatin receptor ligands) solely to improve postoperative biochemical control in acromegaly. Consider this when planning transsphenoidal surgery and evaluating whether to initiate medical pretreatment.

Avoid routine preoperative medical therapy to improve biochemical control

STEP 1 — Gather Information

• Confirm biochemical diagnosis of acromegaly (elevated IGF-1, lack of GH suppression after oral glucose load)
• Document planned transsphenoidal surgery
• Assess for severe pharyngeal thickness, sleep apnea, or high‑output heart failure
• Record baseline IGF‑1 and GH levels, tumor size, and parasellar extent on MRI Action: Proceed to evaluate indications for preoperative SRL.

STEP 2 — Rule In / Rule Out

• Rule in: Presence of severe pharyngeal thickness, sleep apnea, or high‑output heart failure → indicates preoperative SRL may be used to reduce surgical risk (not for biochemical control)
• Rule out: Absence of these features → routine preoperative medical therapy not indicated for improving postoperative biochemical control
  Decision: If ruled in, go to Step 3; if ruled out, go to Step 4.

STEP 3 — Classify or Stratify

• Classify patient as needing preoperative SRL for risk reduction (e.g., to mitigate airway or cardiac complications)
• Select appropriate SRL agent and dose (e.g., octreotide LAR 20 mg monthly or lanreotide autogel 90 mg monthly) to be started preoperatively and continued per standard regimen
  Action: Initiate preoperative SRL for risk reduction; do not aim for biochemical control.

STEP 4 — Decide

• Decide against routine preoperative medical therapy solely to improve postoperative biochemical control
• Proceed with transsphenoidal surgery without preoperative SRL; plan postoperative IGF‑1 measurement at 12 weeks to assess remission
  Action: Withhold preoperative SRL for biochemical control; proceed to surgery.

Clinical Guardrails / Mimics / Pitfalls

• Do not use preoperative SRL solely to normalize IGF‑1 before surgery; no proven benefit in postoperative remission rates and may confound early postoperative testing.
• Avoid delaying surgery for prolonged preoperative medical therapy aiming for biochemical control.
• Preoperative SRL may reduce tumor size and improve surgical safety in high‑risk patients (severe sleep apnea, pharyngeal thickening, high‑output heart failure) but this is for risk mitigation, not biochemical control.
• Pitfall: Misinterpreting early postoperative IGF‑1 suppression due to carryover effect of preoperative SRL as surgical remission; wait ≥12 weeks post‑op and consider washout if needed.

Concrete Clinical Example

A 45‑year‑old with acromegaly (IGF‑1 +2× ULN, nonsuppressed GH) is evaluated for transsphenoidal surgery. He reports mild snoring but has no documented severe pharyngeal thickening, sleep apnea, or high‑output heart failure. Routine preoperative octreotide is not recommended solely to improve postoperative biochemical control. Surgery proceeds without preoperative medical therapy; IGF‑1 is measured at 12 weeks post‑op to assess remission.

Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2700